CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as we...
Phase 2
Scottsdale, Arizona, United States and 3 other locations
open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma...
Phase 2
Scottsdale, Arizona, United States and 3 other locations
(nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma...
Phase 2
Phoenix, Arizona, United States and 5 other locations
for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for ...
Phase 3
Gilbert, Arizona, United States and 197 other locations
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given toge...
Phase 2
Scottsdale, Arizona, United States
as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma...
Phase 2
Phoenix, Arizona, United States and 47 other locations
and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropy...
Phase 1, Phase 2
Scottsdale, Arizona, United States and 19 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Phoenix, Arizona, United States and 67 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Phoenix, Arizona, United States and 138 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Scottsdale, Arizona, United States and 18 other locations
Clinical trials
Research sites
Resources
Legal